Your browser is no longer supported. Please, upgrade your browser.
Halozyme Therapeutics, Inc.
Index- P/E310.00 EPS (ttm)0.15 Insider Own0.80% Shs Outstand136.58M Perf Week8.86%
Market Cap6.60B Forward P/E26.44 EPS next Y1.79 Insider Trans-22.04% Shs Float130.49M Perf Month12.39%
Income21.50M PEG5.34 EPS next Q0.53 Inst Own- Short Float11.85% Perf Quarter65.72%
Sales199.60M P/S33.08 EPS this Y10.50% Inst Trans0.20% Short Ratio7.84 Perf Half Y65.78%
Book/sh0.72 P/B65.88 EPS next Y93.11% ROA4.10% Target Price41.25 Perf Year135.62%
Cash/sh2.49 P/C19.04 EPS next 5Y58.00% ROE24.30% 52W Range12.71 - 47.49 Perf YTD11.05%
Dividend- P/FCF- EPS past 5Y2.10% ROI-13.70% 52W High-0.13% Beta1.53
Dividend %- Quick Ratio16.40 Sales past 5Y21.10% Gross Margin83.10% 52W Low273.17% ATR1.97
Employees132 Current Ratio18.50 Sales Q/Q41.30% Oper. Margin17.30% RSI (14)69.54 Volatility5.33% 4.12%
OptionableYes Debt/Eq3.98 EPS Q/Q248.90% Profit Margin10.80% Rel Volume0.89 Prev Close47.05
ShortableYes LT Debt/Eq3.98 EarningsNov 02 AMC Payout0.00% Avg Volume1.97M Price47.43
Recom2.40 SMA209.91% SMA5016.48% SMA20060.82% Volume1,756,888 Change0.81%
Dec-17-20Initiated Berenberg Buy $50
Sep-14-20Resumed JP Morgan Overweight $28
Jul-01-20Initiated The Benchmark Company Buy $39
Feb-05-20Upgrade Piper Sandler Neutral → Overweight $18 → $27
Jan-09-20Upgrade BMO Capital Markets Market Perform → Outperform $17 → $24
Jan-08-20Initiated Goldman Buy $24
Nov-05-19Upgrade Barclays Underweight → Equal Weight $17 → $16
Oct-19-18Resumed Piper Jaffray Neutral
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Jun-22-15Reiterated JP Morgan Overweight $20 → $25
Mar-03-15Reiterated UBS Buy $16 → $21
Feb-18-15Reiterated MLV & Co Buy $15 → $20
Jan-08-15Reiterated MLV & Co Buy $12 → $15
Jan-15-21 05:30PM  
Jan-14-21 10:46AM  
Jan-13-21 02:17PM  
Jan-12-21 01:24PM  
Jan-11-21 11:22AM  
Jan-08-21 09:57AM  
Jan-06-21 11:13AM  
Jan-05-21 10:59AM  
Jan-04-21 08:00AM  
Dec-31-20 08:52AM  
Dec-23-20 01:30PM  
Dec-21-20 10:01AM  
Dec-19-20 03:52AM  
Dec-16-20 12:00PM  
Dec-14-20 01:05PM  
Dec-10-20 12:47PM  
Dec-09-20 10:42AM  
Dec-08-20 01:32PM  
Dec-04-20 08:50AM  
Dec-02-20 11:30AM  
Nov-27-20 12:00PM  
Nov-25-20 01:14PM  
Nov-24-20 03:08PM  
Nov-23-20 09:12AM  
Nov-18-20 04:01PM  
Nov-17-20 01:16PM  
Nov-13-20 09:59AM  
Nov-12-20 08:15AM  
Nov-05-20 06:40PM  
Nov-04-20 06:54AM  
Nov-03-20 04:14PM  
Nov-02-20 11:31PM  
Oct-26-20 12:31PM  
Oct-22-20 07:30PM  
Oct-21-20 08:38AM  
Oct-20-20 03:16PM  
Oct-06-20 02:14AM  
Sep-28-20 10:40AM  
Sep-17-20 08:00AM  
Sep-10-20 08:01AM  
Sep-09-20 11:30AM  
Sep-02-20 04:01PM  
Aug-11-20 11:18AM  
Aug-10-20 05:25PM  
Aug-04-20 04:05PM  
Aug-03-20 12:31PM  
Jul-29-20 04:05PM  
Jul-28-20 12:32PM  
Jul-23-20 09:49AM  
Jul-17-20 01:30PM  
Jul-09-20 02:46PM  
Jul-01-20 07:20PM  
Jun-29-20 12:54PM  
Jun-22-20 08:00AM  
Jun-19-20 08:32AM  
Jun-17-20 05:08PM  
Jun-16-20 10:01AM  
Jun-13-20 07:09AM  
Jun-10-20 11:30AM  
Jun-04-20 12:35PM  
May-29-20 10:28AM  
May-28-20 08:01AM  
May-20-20 08:32AM  
May-19-20 08:37AM  
May-15-20 11:25AM  
May-14-20 04:01PM  
May-13-20 03:18AM  
May-12-20 09:52AM  
May-11-20 06:35PM  
May-08-20 10:34AM  
May-07-20 08:01AM  
May-01-20 03:16PM  
Apr-30-20 04:56PM  
Apr-28-20 05:05PM  
Apr-26-20 09:40PM  
Apr-13-20 08:44AM  
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelley Kenneth JDirectorJan 04Sale42.915,000214,556194,833Jan 04 05:07 PM
LaBarre Michael J.SVP, Chief Technical OfficerDec 21Sale42.5812,000510,919122,800Dec 21 06:01 PM
Kelley Kenneth JDirectorDec 07Sale41.0035,0861,438,526199,833Dec 07 06:05 PM
Kelley Kenneth JDirectorDec 02Sale41.0031,7921,303,472234,919Dec 02 05:55 PM
Kelley Kenneth JDirectorNov 27Sale41.2510,000412,500266,711Nov 27 05:43 PM
Torley HelenPresident and CEONov 25Option Exercise14.6650,000733,000530,522Nov 25 06:56 PM
Kelley Kenneth JDirectorNov 25Sale41.509,671401,350276,711Nov 27 05:43 PM
Daly James MDirectorNov 25Sale40.4110,363418,80021,002Nov 25 06:57 PM
Henderson Jeffrey WilliamDirectorNov 25Sale40.0824,498981,75747,609Nov 25 06:59 PM
Torley HelenPresident and CEONov 25Sale40.7350,0002,036,568480,522Nov 25 06:56 PM
LaBarre Michael J.SVP, Chief Technical OfficerNov 20Sale38.7612,000465,176134,800Nov 20 06:25 PM
LaBarre Michael J.SVP, Chief Technical OfficerOct 20Sale30.4312,000365,148146,800Oct 20 04:53 PM
LaBarre Michael J.SVP, Chief Technical OfficerSep 21Sale26.9112,000322,884158,800Sep 21 07:30 PM
MATSUI CONNIEDirectorSep 11Sale27.0632,000865,792216,753Sep 14 05:33 PM
Matsuda MasaruSVP, General CounselSep 04Option Exercise0.006,884013,822Sep 04 06:13 PM
LaBarre Michael J.SVP, Chief Technical OfficerAug 20Sale28.3012,000339,564170,800Aug 20 04:21 PM
Daly James MDirectorAug 13Sale29.1234,337999,89331,365Aug 13 06:43 PM
LaBarre Michael J.SVP, Chief Technical OfficerJul 20Sale29.0112,000348,072182,800Jul 20 06:33 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 22Option Exercise7.1418,613132,897194,800May 22 06:39 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 20Option Exercise7.1421,387152,703197,574May 21 04:11 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 20Sale23.8021,387509,075176,187May 21 04:11 PM
Kelley Kenneth JDirectorMar 19Buy14.2352,629748,697277,553Mar 19 07:28 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 22Option Exercise0.0011,3920120,675Feb 24 08:03 PM
Torley HelenPresident and CEOFeb 22Option Exercise0.0039,3540510,033Feb 24 08:02 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 22Option Exercise0.008,8030179,231Feb 24 08:04 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 14Option Exercise0.005,7720172,423Feb 18 04:16 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 14Option Exercise0.007,8090111,983Feb 18 04:15 PM
Torley HelenPresident and CEOFeb 14Option Exercise0.0028,7300484,923Feb 18 04:14 PM
Matsuda MasaruSVP, General CounselFeb 12Option Exercise0.004,13008,619Feb 13 06:41 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 12Option Exercise0.007,8830169,376Feb 13 06:39 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 12Option Exercise0.0011,2620108,068Feb 13 06:38 PM
Torley HelenPresident and CEOFeb 12Option Exercise0.0032,7950472,452Feb 13 06:24 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 03Option Exercise0.0011,5590165,782Feb 04 04:24 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 03Option Exercise0.0023,1190105,081Feb 04 04:21 PM
Torley HelenPresident and CEOFeb 03Option Exercise0.0055,4870459,567Feb 04 04:18 PM